Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Lipid pharmacotherapy for treatment of atherosclerosis|
|Citation:||Expert Opinion on Pharmacotherapy, 2014; 15(8):1119-1125|
|Stephen J Nicholls, Anthony D Pisaniello, Yu Kataoka & Rishi Puri|
|Abstract:||INTRODUCTION: For more than two decades, lowering levels of low-density lipoprotein cholesterol has formed the cornerstone of management of patients with atherosclerotic cardiovascular disease. The substantial residual risk of clinical events in patients treated with statin therapy highlights the need to develop more effective strategies to reduce cardiovascular risk. AREAS COVERED: Current and future approaches targeting dyslipidemia and inflammatory factors implicated in atherosclerosis are discussed. EXPERT OPINION: Considerable efforts to further reduce levels of atherogenic lipoproteins provide additional strategies to lower cardiovascular risk. In contrast, it remains to be determined whether targeting protective lipid factors or inflammatory mediators of atherosclerosis will be clinically beneficial.|
|Keywords:||atherosclerosis; lipids; medical therapies; risk factors|
|Rights:||© 2014 Informa UK|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.